



Roundtable: Financing biotech and life science companies - U.S. and European opportunities

Roundtable speakers



Rodolphe Besserve

Director Corporate Finance Healthcare - Société Générale

- Director in Biotech / Medtech Corporate Finance
- Executed more than 30 deals over the last 5 years (IPOs, right issues, private placements, M&A transactions)
- Former Research Analyst and opinion leader in the Biotech / Medtech sector (10 years of experience)
- 6 years as Head of Biotech Research at Société Générale
- Prior to joing Société Générale, Rodolphe worked for Kepler Equities and Bryan Garnier, as Head of Mid-cap and Big Pharma coverage
- · Rodolphe has an chemical engineering background and graduated from EM Lyon in Finance



André Choulika

CEO, Cellectis

Dr. André Choulika, Ph.D. is the Founder of Cellectis SA and has been its Chief Executive Officer since 1999 and as its Chairman since June 27, 2011. Dr. Choulika is a pioneer in the analysis and use of Meganucleases to modify complex genomes. Dr. Choulika has made many of the critical observations in the field and is an author of the most significant patents on the use of Meganucleases in vivo. He has been Chairman of Calyxt, Inc. since August 2010. He serves as the Chairman of France Biotech. He serves as a Director of Cellectis SA. Dr. Choulika is a Member of Investment Committee at G1J Ile-de-France SA, SCR. He received a Ph.D. in Molecular Virology from the University of Paris VI / Institut Pasteur. Dr. Choulika has made post-doctoral studies at the Harvard Medical School within the department of Molecular Medicine of Boston's Children's Hospital.

Roundtable: Financing biotech and life science companies - U.S. and European opportunities



Evelyne NguyenCEO, ANMPAR TNERS

Evelyne graduated from ISG (Institut Supérieur de Gestion) and Stanford (SEP 2003).

After starting her career in the Food industries she specialized in the Pharma/Biotech domains mainly with Bristol Myers Squibb and LFB (Laboratoire français du Fractionnement et des Biotechnologies) – France where she was appointed CFO - SVP Finance & Strategy, member of the Group's Executive Committee, then EVP Bio manufacturing.

She founded in 2013 ANMPartners, a Finance, Strategy and Business Development advisory firm dedicated to Healthcare industries.

With intimate knowledge of biopharmaceutical specifics and native Asian culture, Evelyne's key track records are related to M&As, strategic project management and financing.

Evelyne is member of SCF Board since 2012 and served as Treasurer from 2012 to 2014.

She is active in organizing corporate events, with key interests vis-à-vis Asia and pharma/Biotech sectors.

Evelyne key role is to develop SCF relations with private & public companies and corporate structures.



Pierre-Louis PérinPartner, Reed Smith

Pierre-Louis Périn is partner in the Corporate Department of Reed Smith in Paris

He specialises in Venture Capital and Private Equity and also advises on the structuring of private equity management companies and funds. He also has expertise in corporate governance, incentive schemes, shareholders disputes, as well as in M&A (domestic and international) and joint ventures.

Pierre-Louis is an affiliate professor at Sciences Po Paris and an active member of the FranceInvest (French Venture Capital Association)'s commissions on venture capital, ethics and training. Pierre-Louis is a graduate of Sciences Po Paris and holds a Law PHD from University Paris II - Panthéon Assas.

After ten years in the legal departments of financial and industrial groups, Pierre-Louis became an avocat and is a member of the Paris bar since 1997. He joined SJ Berwin (then King & Wood Mallesons) as a partner in 2001 and Reed Smith in 2017.

BEIJING **CENTURY CITY** CHICAGO DUBAL **FRANKFURT** HONG KONG HOUSTON KAZAKHSTAN LONDON LOS ANGELES MIAMI MUNICH **NEW YORK** PARIS PHII ADEI PHIA PITTSBURGH PRINCETON RICHMOND SAN FRANCISCO SHANGHAI SILICON VALLEY SINGAPORE TYSONS WASHINGTON, D.C. WILMINGTON

ABU DHABI

ATHENS AUSTIN